NCT06657456

Brief Summary

The aim of this randomized, parallel, two-arm, placebo-controlled, triple-blind clinical trial is to evaluate the efficacy of a phytosterol- and phytostanol-rich extract on lipid profile parameters in individuals with hypercholesterolemia, focusing primarily on total cholesterol and LDL cholesterol levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 19, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 24, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

January 8, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2025

Completed
Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

October 19, 2024

Last Update Submit

April 28, 2026

Conditions

Keywords

CholesterolCholesterol, ElevatedHypercholesterolaemiaLipid Metabolism DisordersDyslipidemias

Outcome Measures

Primary Outcomes (1)

  • Blood lipid profile

    Includes total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides

    Day 1, at 28 and 56 days

Secondary Outcomes (8)

  • Anthropometric parameters

    Day 1, at 28 and 56 days

  • Body composition measures

    Day 1, at 28 and 56 days

  • Oxidation markers

    Day 1, at 28 and 56 days

  • Dietary Intake

    Day 1, at 28 and 56 days

  • Adherence to the Mediterranean diet

    Day 1, at 28, and 56 days

  • +3 more secondary outcomes

Study Arms (2)

Experimental

EXPERIMENTAL

Consumption of dietary supplement capsules for 56 days.

Dietary Supplement: Phytosterol-rich extract

Control Group

PLACEBO COMPARATOR

Identically appearing placebo capsules consumed for 56 days.

Dietary Supplement: Placebo

Interventions

Phytosterol-rich extractDIETARY_SUPPLEMENT

Experimental product: extract rich in phytosterols

Experimental
PlaceboDIETARY_SUPPLEMENT

Product with identical characteristics to the experimental product.

Control Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (age \> 18 YO)
  • Total cholesterol levels at screening ≥ 200 mg/dL

You may not qualify if:

  • History of allergic hypersensitivity or poor tolerance to any component of the products under study.
  • Use of prescribed medication which may interfere with study measurements.
  • Unwillingness or inability to comply with clinical trial procedures.
  • Subjects whose condition makes them ineligible for the study at the investigator's discretion.
  • Pregnant or having the wish to become pregnant, or lactating.
  • Recent participation in another nutritional or medical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCAM San Antonio Catholic University of Murcia

Murcia, Murcia, 30107, Spain

Location

MeSH Terms

Conditions

HypercholesterolemiaLipid Metabolism DisordersDyslipidemias

Condition Hierarchy (Ancestors)

HyperlipidemiasMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Desirée Victoria Montesinos

    Universidad Católica San Antonio de Murcia

    PRINCIPAL INVESTIGATOR
  • Ana Mª García Muñoz

    Universidad Católica San Antonio de Murcia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 19, 2024

First Posted

October 24, 2024

Study Start

January 8, 2025

Primary Completion

April 10, 2025

Study Completion

May 30, 2025

Last Updated

May 4, 2026

Record last verified: 2026-04

Locations